Addressing Metabolic Dysfunction‑Associated Steatotic Liver Disease (MASLD) in Endocrinology Settings in Canada: From Prevalence to Patient-Centered Management

Auteurs-es

  • Akshay Jain

Résumé

Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in Canadian endocrinology, affecting up to 70% of those with type 2 diabetes and 75% with obesity. Despite this, routine screening is rare, leading to missed detection and intervention. Advanced fibrosis, observed in 15% of cases, increases the risk of liver and cardiovascular complications. This article addresses the burden of MASLD and the need for systemic screening and patient-centred care to improve outcomes and reduce Canada’s disease burden.

Biographie de l'auteur-e

Akshay Jain

Dr. Akshay Jain is the first Canadian physician to be triple board‑certified by the American Boards in Endocrinology, Internal Medicine and Obesity Medicine. He is the only Canadian to have won the AACE Rising Star in Endocrinology Award (2022) and to feature on Medscape’s list of 25 Top Rising Stars of Medicine (2020). He practices in Surrey, BC and is a Clinical Instructor in the Division of Endocrinology at the University of British Columbia. He is fluent in 6 languages: English, Hindi, Gujarati, Marathi, Marwari, and Urdu. In 2022, he won the Top 25 Canadian Immigrant Award.

Références

Kim J, Raggi P, Carreau AM, Wharton S, Cheng AYY, Swain MG. A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada. Diabetes Obes Metab. Published online September 12, 2025. doi: 10.1111/dom.70117.

Diabetes Canada Clinical Practice Guidelines Expert Working Group:, Kim J, Bajaj HS, Ramji A, Bemeur C, Sebastiani G. Diabetes and metabolic dysfunction-associated steatotic liver disease in adults: a clinical practice guideline. Can J Diabetes. 2025;49(4):222-236. doi: 10.1016/j.jcjd.2025.04.003

Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2025;393(7):683-698. doi: 10.1056/NEJMra2412865

Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-1082. doi: 10.2337/dci24-0094

Horn P, Tacke F. Key takeaways from the updated multidisciplinary European MASLD guidelines. eGastroenterology. 2025;3(2):e100196. Published 2025 Jun 8. doi: 10.1136/egastro-2025-100196

Mahmoud MC, Abdelmalek MF. The liver in diabetes and metabolic syndrome. Clin Liver Dis. 2025;29(3):407-429. doi: 10.1016/j.cld.2025.04.003

Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, Duseja A, et al. Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis. Gastroenterology. 2025;169(5):1017-1032.e2. doi: 10.1053/j.gastro.2025.02.044

Téléchargements

Publié

2025-12-16

Comment citer

Addressing Metabolic Dysfunction‑Associated Steatotic Liver Disease (MASLD) in Endocrinology Settings in Canada: From Prevalence to Patient-Centered Management. (2025). Canadian Diabetes & Endocrinology Today, 3(s01), 2–8. https://doi.org/10.58931/cdet.2025.3s0144

Numéro

Special Supplement, Fall 2025

Rubrique

Articles

Licence

© Canadian Diabetes & Endocrinology Today 2025

Licence Creative Commons

Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.

Comment citer

Addressing Metabolic Dysfunction‑Associated Steatotic Liver Disease (MASLD) in Endocrinology Settings in Canada: From Prevalence to Patient-Centered Management. (2025). Canadian Diabetes & Endocrinology Today, 3(s01), 2–8. https://doi.org/10.58931/cdet.2025.3s0144

Articles les plus lus du,de la,des même-s auteur-e-s